Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Holm Nørgaard, Caroline; Friedrich, Sarah; T. Hansen, Charlotte; Alexander Gerds, Thomas; Ballard, Clive; Vega Møller, Daniél; Bjerre Knudsen, Lotte; Kvist, Kajsa; Zinman, Bernard; Holm, Ellen; Torp‐Pedersen, Christian; Steinrud Mørch, Lina

doi:10.1002/trc2.12268

Public

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Published in Alzheimer s & Dementia Translational Research & Clinical Interventions • Jan 1, 2022

Authors:

Caroline Holm Nørgaard

Sarah Friedrich

Charlotte T. Hansen

Abstract

INTRODUCTION: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people w...

Subject

Dementia

Medical prescription

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!